Reference health
Non Platinum Metal Complexes as Anti‐cancer Drugs
114/114 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
13 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 114 checked references that resolve
resolves10.1038/205698a0
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
resolves10.2174/0929867054637626
Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
resolves10.1002/pauz.200500161
Medizinische Chemie der Platinkomplexe: Besonderheiten anorganischer Zytostatika
resolves10.1016/j.jinorgbio.2006.05.014
Investigations of the possible pharmacological effects of organotin(II) complexes
resolves10.1016/S1040-8428(01)00222-0
Rhodium and its compounds as potential agents in cancer treatment
resolves10.1002/(SICI)1521-4184(20004)333:4<93::AID-ARDP93>3.0.CO;2-N
Cytotoxic Activity of Cerium Complexes with Coumarin Derivatives. Molecular Modeling of the Ligands
resolves10.1016/0360-3016(89)90914-0
High efficiency of ferricenium salts as radiosensitizers of V79 cells in vitro and the kht tumor in vivo
resolves10.1016/S0020-1693(00)00147-X
On the mechanism of the antitumor activity of ferrocenium derivatives
resolves10.1021/jm021003k
Water Stability and Cytotoxic Activity Relationship of a Series of Ferrocenium Derivatives. ESR Insights on the Radical Production during the Degradation Process
resolves10.1002/ange.200502925
Ferrocene‐Mediated Proton‐Coupled Electron Transfer in a Series of Ferrocifen‐Type Breast‐Cancer Drug Candidates
resolves10.1002/cmdc.200500035
A Series of Unconjugated Ferrocenyl Phenols: Prospects as Anticancer Agents
resolves10.1016/j.ica.2005.04.010
Synthesis of redox-active ferrocene pyrazole conjugates and their cytotoxicity in human mammary adenocarcinoma MCF-7 cells
resolves10.1021/ol060868f
Enantioselective Synthesis of Ferrocenyl Nucleoside Analogues with Apoptosis-Inducing Activity
resolves10.1039/b507687k
Highly cytotoxic iron(ii) complexes with pentadentate pyridyl ligands as a new class of anti-tumor agents
resolves10.1016/j.freeradbiomed.2005.12.001
Dinitrosyl-iron triggers apoptosis in Jurkat cells despite overexpression of Bcl-2
resolves10.1107/S0108768183003249
The structure of LaF<sub>3</sub> – a single-crystal neutron diffraction study at room temperature
resolves10.1016/S0020-1693(00)00139-0
Acetylenehexacarbonyldicobalt complexes, a novel class of antitumor drugs
resolves10.1021/ja01582a036
Acetylenic Dicobalt Hexacarbonyls. Organometallic Compounds Derived from Alkynes and Dicobalt Octacarbonyl<sup>1,2</sup>
resolves10.1016/0022-328X(72)80037-8
On the stability of α-(alkynyl)dicobalt hexacarbonyl carbonium ions
resolves10.1002/1521-3765(20010417)7:8<1589::AID-CHEM15890>3.0.CO;2-1
Advances in the Pauson-Khand Reaction: Development of Reactive Cobalt Complexes
resolves10.1002/1521-3773(20010316)40:6<1040::AID-ANIE10400>3.0.CO;2-P
Labeling of Biomolecules for Medicinal Applications—Bioorganometallic Chemistry at Its Best
resolves10.1002/anie.199207531
Estradiols Modified by Metal Carbonyl Clusters as Suicide Substrates for the Study of Receptor Proteins: Application to the Estradiol Receptor
resolves10.1002/ardp.19973300604
Bioorganometallic Chemistry – Synthesis and Antitumor Activity of Cobalt Carbonyl Complexes
resolves10.1021/jm049326z
Antitumor-Active Cobalt−Alkyne Complexes Derived from Acetylsalicylic Acid: Studies on the Mode of Drug Action
resolves10.1016/j.jinorgbio.2003.12.008
Investigations on the effects of cobalt-alkyne complexes on leukemia and lymphoma cells: cytotoxicity and cellular uptake
resolves10.1016/j.jinorgbio.2006.06.013
Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining acetylenehexacarbonyldicobalt complexes with the tyrosine kinase inhibitor imatinib
resolves10.1039/b504294c
Synthesis, cytotoxicity, cellular uptake and influence on eicosanoid metabolism of cobalt–alkyne modified fructoses in comparison to auranofin and the cytotoxic COX inhibitor Co-ASS
resolves10.1007/s10534-004-6252-z
Stability, protein binding and thiol interaction studies on [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt
resolves10.2174/138955706777698660
Cyclooxygenases in Cancer: Chemoprevention and Sensitization to Conventional Therapies
resolves10.1021/jm00065a006
Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards
resolves10.1016/S0162-0134(97)00090-1
Bis-tropolonato derivatives of Cobalt(III) complexes of bidentate aliphatic nitrogen mustards as potential hypoxia-selective cytotoxins
resolves10.2307/3576865
Some Complexes of Cobalt(III) and Iron(III) Are Radiosensitizers of Hypoxic EMT6 Cells
resolves10.1667/RR3229
Optimization of the Auxiliary Ligand Shell of Cobalt(III)(8-hydroxyquinoline) Complexes as Model Hypoxia-Selective Radiation-Activated Prodrugs
resolves10.1016/j.bcp.2006.03.007
Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator
resolves10.1002/anie.199623951
New Course in the Search for Antitumor Agents: The Use of pH‐Dependent Sources of Reactive Radicals
resolves10.1021/jm00281a001
Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes
resolves10.1016/0014-4827(76)90617-0
Comparison of different methods of determining cell viability after exposure to cytotoxic compounds
resolves10.1002/1097-0142(197912)44:6<1965::AID-CNCR2820440602>3.0.CO;2-6
Inhibitory effects of a new oral gold compound on hela cells
resolves10.1016/0006-2952(87)90715-5
Cellular interactions of auranofin and a related gold complex with raw 264.7 macrophages
resolves10.1016/S0010-8545(02)00048-6
Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria
resolves10.1021/jm00152a009
Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes
resolves10.1016/0041-008X(87)90131-1
The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes
resolves10.1016/0041-008X(87)90130-X
The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes
resolves10.1016/0041-008X(89)90110-5
The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes
resolves10.1007/s002800000166
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes
resolves10.1016/0041-008X(89)90315-3
In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit
resolves10.1046/j.1432-1327.2000.01703.x
Thioredoxin reductase as a pathophysiological factor and drug target
resolves10.1038/sj.bjp.0704823
Induction of mitochondrial permeability transition by auranofin, a Gold(I)‐phosphine derivative
resolves10.1016/j.bcp.2003.09.038
Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c
resolves10.1002/ange.200502756
Gold(<scp>I</scp>)‐Phosphinkomplexe für die irreversible Hemmung von humanen Disulfid‐Reduktasen
resolves10.1074/jbc.M412519200
Mechanistic Studies on a Novel, Highly Potent Gold-Phosphole Inhibitor of Human Glutathione Reductase
resolves10.1016/S0162-0134(96)00190-0
Biological properties of two gold(III) complexes: AuCl3 (Hpm) and AuCl2 (pm)
resolves10.1097/00001813-200606000-00007
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds
resolves10.1021/jm0509288
Gold(III) Dithiocarbamate Derivatives for the Treatment of Cancer: Solution Chemistry, DNA Binding, and Hemolytic Properties
resolves10.2174/0929867003374066
Antitumour Metallocenes: Structure-Activity Studies and Interactions with Biomolecules.
resolves10.1007/BF00873139
Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane
resolves10.1200/JCO.1998.16.8.2761
Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.
resolves10.1007/s002800050838
Phase II trial of titanocene dichloride in advanced renal-cell carcinoma
resolves10.1159/000027075
Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer
resolves10.1038/bjc.1998.352
Anti-proliferative activity and mechanism of action of titanocene dichloride
resolves10.1007/s007750100248
Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride
resolves10.1021/cr040704h
Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology
resolves10.1016/S0162-0134(00)00198-7
Inhibition of human topoisomerase II by the antitumor metallocenes
resolves10.1007/BF00304090
The in vivo inhibition of tumor growth by ruthenium red: its relationship with the metabolism of calcium in the tumor
resolves10.2174/1381612033454180
Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
resolves10.1016/j.jinorgbio.2006.02.013
From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
resolves10.1007/s00280-004-0773-6
Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines
resolves10.1038/sj.bjc.6600176
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
resolves10.1038/sj.bjc.6600906
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
resolves10.1158/1078-0432.CCR-03-0746
A Phase I and Pharmacological Study with Imidazolium-<b>
<i>trans-</i>
</b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
resolves10.1016/j.jinorgbio.2004.04.002
A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins
resolves10.1007/s00432-004-0617-0
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
resolves10.1016/j.canlet.2005.01.002
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells
resolves10.1039/b309160k
Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy
resolves10.1016/0006-2952(96)00106-2
Cellular distribution and cellular reactivity of platinum(II) complexes
resolves10.1002/pauz.200500160
Tumorhemmende Metallverbindungen: Entwicklung, Bedeutung und Perspektiven
resolves10.1021/jm0490742
Redox-Active Antineoplastic Ruthenium Complexes with Indazole: Correlation of in Vitro Potency and Reduction Potential
resolves10.1039/b511792e
Redox behavior of tumor-inhibiting ruthenium(
<scp>iii</scp>
) complexes and effects of physiological reductants on their binding to GMP
resolves10.1073/pnas.68.7.1623
Antitumor Activity and Toxicity of Salts of Inorganic Group IIIa Metals: Aluminum, Gallium, Indium, and Thallium
resolves10.1016/0277-5379(82)90212-7
Tumor cell toxicity of stable gallium nitrate: Enhancement by transferrin and protection by iron
resolves10.1016/S0065-2571(96)00010-6
Antineoplastic drugs that interfere with iron metabolism in cancer cells
resolves10.1016/0047-0740(81)90037-1
Relationship of iron metabolism to tumor cell toxicity of stable gallium salts
resolves10.1200/JCO.1994.12.11.2271
Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma.
resolves10.1097/00000421-199806000-00017
Vinblastine, Ifosfamide, Gallium Nitrate, and Filgrastim in Platinum- and Paclitaxel-Resistant Ovarian Cancer
resolves10.1159/000030430
A Phase II Trial of Gallium Nitrate in Patients with Androgen-Metastatic Prostate Cancer
resolves10.5414/CPP43590
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW
The 13 references without a DOI — listed, not checked
no DOI — not checkede_1_2_1_34_2
no DOI — not checkedK.Schmidt PhD thesis Freie Universität Berlin 2000.
no DOI — not checkede_1_2_1_37_2
no DOI — not checkede_1_2_1_49_2
no DOI — not checkede_1_2_1_55_2
no DOI — not checkede_1_2_1_56_2
no DOI — not checkede_1_2_1_64_2
no DOI — not checkede_1_2_1_66_2
no DOI — not checkede_1_2_1_82_2
no DOI — not checkede_1_2_1_92_2
no DOI — not checkede_1_2_1_94_2
no DOI — not checkede_1_2_1_102_2
no DOI — not checkede_1_2_1_117_2
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1002/ardp.200600151"><img src="https://citestamp.com/citestamped/10.1002/ardp.200600151/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1002/ardp.200600151)